
Bayer announced positive topline results from Phase III trial OASIS 3, evaluating elinzanetant versus placebo for treating moderate to severe vasomotor symptoms (VMS) in menopausal women. Elinzanetant significantly reduced VMS frequency over 12 weeks compared to placebo, meeting the primary endpoint. The 52-week safety profile aligns with prior studies. Member of the Executive Committee of Bayer of Bayer expressed confidence in elinzanetant's efficacy based on consistent Phase III data. Additionally, the Principal Investigator highlighted the importance of expanding treatment options for menopausal symptoms. OASIS 3 joins two previous successful Phase III trials, with all results set for presentation at medical conferences. Bayer plans to seek regulatory approval for elinzanetant based on OASIS 1, 2, and 3 data.
Like
Save
Share